Synthon Biopharmaceuticals has been working in biotechnology since 2007. Our ambition is to be best-in-class or first-in-class with innovative products based on new biological and new chemical entities. Our growing portfolio reflects our focus and commitment to bringing medicines to patients with a high unmet medical need, notably in oncology and autoimmune diseases.

We are well-positioned to build on the success, infrastructure and organization of the financially strong, privately held parent company. This distinguishes us from other biotech companies and also allows us to make creative choices and to be flexible and dynamic.

State-of-the-art laboratories

We have built state-of-the-art biopharmaceutical research laboratories and GMP facilities for manufacturing monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) - up to Phase III clinical trials and early launches - both for our own portfolio and to support commercial licensees of our ADC technology. 

Strong scientific knowledge base

Our investment in infrastructure and technology is matched by our investment in people. Since the inception of our innovative business, we have gradually built an organization incorporating all the expertise necessary to bring innovative drug candidates to the market.

read more

Synthon Biopharmaceuticals is a member of several national and international platforms.

read more

Partnering and licensing opportunities

We offer selected external parties access to our linker-drug and conjugation technology and (GMP) manufacturing capabilities for (site-specific) conjugation of their own proprietary monoclonal antibodies.

read more

Press releases
25 Jan 2018

Synthon’s [vic-]trastuzumab duocarmazine (SYD985) granted FDA Fast Track designation for pre-treated HER2-positive metastatic breast cancer

read more
15 Mar 2017

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

read more
02 Mar 2020 - 05 Mar 2020 - Hotel Novotel London West, London, UK

10th Annual World ADC Europe

World ADC London is Europe’s longest standing and most comprehensive forum with a sole focus on antibody drug conjugates.

read more
28 Apr 2020 - 01 May 2020 - RAI, Amsterdam, the Netherlands

BioProcess International Europe

Europe’s leading BioProcessing event for accelerating biologics, mAbs, vaccines and novel products to commercial success.

read more